Resistance to Targeted Anti-Cancer Therapeutics – serie

Visar alla böcker i serien Resistance to Targeted Anti-Cancer Therapeutics. Handla med fri frakt och snabb leverans.

40 produkter

Kategorier

40 produkter

Del 1 - Resistance to Targeted Anti-Cancer Therapeutics
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
Targeted Therapies to Reverse Resistance
AvBenjamin Bonavida
Inbunden, Engelska, 2013
1 674 kr
Skickas inom 10-15 vardagar
This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.
Del 2 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Immunotherapeutic Antibodies in Cancer
Strategies to Overcome Resistance
AvBenjamin Bonavida
Inbunden, Engelska, 2013
1 674 kr
Skickas inom 10-15 vardagar
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Del 2 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Immunotherapeutic Antibodies in Cancer
Strategies to Overcome Resistance
AvBenjamin Bonavida
Häftad, Engelska, 2015
1 674 kr
Skickas inom 10-15 vardagar
The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.
Del 1 - Resistance to Targeted Anti-Cancer Therapeutics
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
Targeted Therapies to Reverse Resistance
AvBenjamin Bonavida
Häftad, Engelska, 2015
1 674 kr
Skickas inom 10-15 vardagar
This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.
Del 18 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Ibritumomab in Lymphoma
AvMakoto Hosono,Jean-François Chatal
Häftad, Engelska, 2019
1 119 kr
Skickas inom 10-15 vardagar
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Del 17 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
AvAndrés J. M. Ferreri
Häftad, Engelska, 2019
1 341 kr
Skickas inom 10-15 vardagar
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
AvYosef Yarden,Moshe Elkabets
Häftad, Engelska, 2019
2 127 kr
Skickas inom 5-8 vardagar
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression.
Del 19 - Resistance to Targeted Anti-Cancer Therapeutics
Cancer Stem Cell Resistance to Targeted Therapy
AvCristina Maccalli,Matilde Todarom. fl.
Inbunden, Engelska, 2019
1 119 kr
Skickas inom 10-15 vardagar
This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
Del 19 - Resistance to Targeted Anti-Cancer Therapeutics
Cancer Stem Cell Resistance to Targeted Therapy
AvCristina Maccalli,Matilde Todarom. fl.
Häftad, Engelska, 2020
1 119 kr
Skickas inom 10-15 vardagar
This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
Current Applications for Overcoming Resistance to Targeted Therapies
Springer Nature Switzerland AG
2019
1 319 kr
Skickas inom 10-15 vardagar
Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
Del 20 - Resistance to Targeted Anti-Cancer Therapeutics
Current Applications for Overcoming Resistance to Targeted Therapies
AvMyron R. Szewczuk,Bessi Qorrim. fl.
Häftad, Engelska, 2020
1 119 kr
Skickas inom 10-15 vardagar
Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
Del 21 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Targeted Therapies in Lymphomas
AvAna C. Xavier,Mitchell S. Cairo
Inbunden, Engelska, 2019
1 119 kr
Skickas inom 10-15 vardagar
Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.
Del 21 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Targeted Therapies in Lymphomas
AvAna C. Xavier,Mitchell S. Cairo
Häftad, Engelska, 2020
1 119 kr
Skickas inom 10-15 vardagar
Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.
Del 22 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Targeted Therapies in Multiple Myeloma
AvSilvia CW Ling,Steven Trieu
Inbunden, Engelska, 2021
1 563 kr
Skickas inom 10-15 vardagar
Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will beuseful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
Del 22 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Targeted Therapies in Multiple Myeloma
AvSilvia CW Ling,Steven Trieu
Häftad, Engelska, 2022
1 563 kr
Skickas inom 10-15 vardagar
Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors.This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will beuseful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers.This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
Resistance to Proteasome Inhibitors in Cancer
Molecular Mechanisms and Strategies to Overcome Resistance
AvQ. Ping Dou
Inbunden, Engelska, 2014
1 674 kr
Skickas inom 10-15 vardagar
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Resistance to Targeted ABC Transporters in Cancer
AvThomas Efferth
Inbunden, Engelska, 2014
1 119 kr
Skickas inom 10-15 vardagar
This critical review volume explores the theme of ABC transporters in the context of basic cancer research and its role in drug-resistant tumors. The chapters provided complement basic research by including investigations from translational applications to clinical oncology. The development of resistance is a major obstacle in cancer chemotherapy and the field has been moving rapidly in terms of determining the mechanisms for blocking ABC transporter-mediated drug efflux by specific inhibitors and thereby overcoming multidrug resistance. The volume covers these issues in careful detail. Additional topics include the relevance of ABC transporters in resistance to novel and established anticancer drugs and prognosis of patients to compounds, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors and of nanotechnology to combat drug-resistant tumors is also discussed.
Del 5 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Photodynamic Therapy in Cancer
AvValentina Rapozzi,Giulio Jori
Inbunden, Engelska, 2015
1 119 kr
Skickas inom 10-15 vardagar
This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.
Del 6 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Immunotoxins in Cancer Therapy
AvRama Shanker Verma,Benjamin Bonavida
Inbunden, Engelska, 2015
1 119 kr
Skickas inom 10-15 vardagar
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Del 7 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance of Cancer Cells to CTL-Mediated Immunotherapy
AvBenjamin Bonavida,Salem Chouaib
Inbunden, Engelska, 2015
1 119 kr
Skickas inom 10-15 vardagar
This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.
Del 8 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Aromatase Inhibitors in Breast Cancer
AvAlexey Larionov
Inbunden, Engelska, 2015
1 119 kr
Skickas inom 10-15 vardagar
Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.
Resistance to Proteasome Inhibitors in Cancer
Molecular Mechanisms and Strategies to Overcome Resistance
AvQ. Ping Dou
Häftad, Engelska, 2016
1 674 kr
Skickas inom 10-15 vardagar
The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.
Resistance to Targeted ABC Transporters in Cancer
AvThomas Efferth
Häftad, Engelska, 2016
1 477 kr
Skickas inom 5-8 vardagar
This critical review volume explores the theme of ABC transporters in the context of basic cancer research and its role in drug-resistant tumors. The chapters provided complement basic research by including investigations from translational applications to clinical oncology. The development of resistance is a major obstacle in cancer chemotherapy and the field has been moving rapidly in terms of determining the mechanisms for blocking ABC transporter-mediated drug efflux by specific inhibitors and thereby overcoming multidrug resistance. The volume covers these issues in careful detail. Additional topics include the relevance of ABC transporters in resistance to novel and established anticancer drugs and prognosis of patients to compounds, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors and of nanotechnology to combat drug-resistant tumors is also discussed.
Del 5 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Photodynamic Therapy in Cancer
AvValentina Rapozzi,Giulio Jori
Häftad, Engelska, 2016
1 119 kr
Skickas inom 10-15 vardagar
This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.
Del 8 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Aromatase Inhibitors in Breast Cancer
AvAlexey Larionov
Häftad, Engelska, 2016
1 119 kr
Skickas inom 10-15 vardagar
Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.
Del 6 - Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Immunotoxins in Cancer Therapy
AvRama Shanker Verma,Benjamin Bonavida
Häftad, Engelska, 2016
1 119 kr
Skickas inom 10-15 vardagar
This book will be a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance.
Del 9 - Resistance to Targeted Anti-Cancer Therapeutics
Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
AvEmmanuel Donnadieu
Inbunden, Engelska, 2016
1 119 kr
Skickas inom 10-15 vardagar
This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
Resistance to Tyrosine Kinase Inhibitors
AvDaniele Focosi
Inbunden, Engelska, 2016
1 674 kr
Skickas inom 10-15 vardagar
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
Resistance to Targeted Therapies Against Adult Brain Cancers
AvAmanda Tivnan
Inbunden, Engelska, 2016
1 674 kr
Skickas inom 10-15 vardagar
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.
Resistance to Molecular Therapies for Hepatocellular Carcinoma
AvAugusto Villanueva
Inbunden, Engelska, 2017
1 674 kr
Skickas inom 10-15 vardagar
This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

Resistance to Targeted Anti-Cancer Therapeutics – serie

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

Resistance to Ibritumomab in Lymphoma

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Cancer Stem Cell Resistance to Targeted Therapy

Cancer Stem Cell Resistance to Targeted Therapy

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Multiple Myeloma

Resistance to Targeted Therapies in Multiple Myeloma

Resistance to Proteasome Inhibitors in Cancer

Resistance to Targeted ABC Transporters in Cancer

Resistance to Photodynamic Therapy in Cancer

Resistance to Immunotoxins in Cancer Therapy

Resistance of Cancer Cells to CTL-Mediated Immunotherapy

Resistance to Aromatase Inhibitors in Breast Cancer

Resistance to Proteasome Inhibitors in Cancer

Resistance to Targeted ABC Transporters in Cancer

Resistance to Photodynamic Therapy in Cancer

Resistance to Aromatase Inhibitors in Breast Cancer

Resistance to Immunotoxins in Cancer Therapy

Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy

Resistance to Tyrosine Kinase Inhibitors

Resistance to Targeted Therapies Against Adult Brain Cancers

Resistance to Molecular Therapies for Hepatocellular Carcinoma